^
    4years
    [VIRTUAL] C-KIT inhibitors alone or in combination with anti-PD-1 antibodies as a therapeutic option for metastatic acral or mucosal melanoma: a case series (ADO 2020)
    The 3rd patient, who was treated first-line with ipilimumab (Ipi) and Nivo, had to discontinue therapy due to autoimmune (AI) colitis grade 3 according to CTCAE. The 4th patient received multiple previous therapies (pembrolizumab (Pembro) + IDO ‐ 1 inhibitor, Ipi + Nivo, paclitaxel + nintedanib, imatinib, Nivo + LAG 3 inhibitor, imatinib)...showed a full remission with good tolerability after 6 months with pembro + nilotinib, the 2nd patient showed stable results after 2 doses of Ipi + Nivo in combination with nilotinib, but developed grade 3 AI gastritis... C ‐ KIT inhibitors alone or in combination with ICI can represent an effective treatment option with good tolerability for c ‐ KIT mutated MM after failure of standard ICI therapy and exhaustion of study therapy options.
    Clinical • Combination therapy • PD(L)-1 Biomarker • IO biomarker
    |
    LAG3 (Lymphocyte Activating 3)
    |
    KIT mutation • KIT D816V • KIT L576P • KIT V559D
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • paclitaxel • imatinib • Tasigna (nilotinib) • nintedanib